ICU (SeaStar Medical Holding Corporation Common Stock) Stock Analysis - News

SeaStar Medical Holding Corporation Common Stock (ICU) is a publicly traded Healthcare sector company. As of May 21, 2026, ICU trades at $4.02 with a market cap of $15.99M and a P/E ratio of -0.67. ICU moved +1.54% today. Year to date, ICU is +53.28%; over the trailing twelve months it is -69.11%. Its 52-week range spans $2.07 to $44.90. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ICU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in ICU news today?

SeaStar Medical Secures $23.9M Funding, Hits 50% Enrollment in AKI Trial: SeaStar Medical added 13 pediatric hospital customers, raising its QUELIMMUNE base to 16, secured $23.9 million in capital, and cut $3.1 million in liabilities. It enrolled 181 of 339 patients (over 50%) in its NEUTRALIZE-AKI trial and projects roughly $2 million in net product revenue for 2026.

ICU Key Metrics

Key financial metrics for ICU
MetricValue
Price$4.02
Market Cap$15.99M
P/E Ratio-0.67
EPS$-5.86
Dividend Yield0.00%
52-Week High$44.90
52-Week Low$2.07
Volume56
Avg Volume0
Revenue (TTM)$1.23M
Net Income$-12.15M
Gross Margin95.70%

Latest ICU News

Recent ICU Insider Trades

  • Baird Jennifer A bought 4.20K (~$987.42) on Dec 19, 2025.
  • Messinger Michael bought 14.50K (~$5.10K) on Dec 9, 2025.
  • Van Heel Kenneth bought 10.00K (~$8.56K) on Aug 27, 2025.

ICU Analyst Consensus

1 analysts cover ICU: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about ICU

What changed in ICU news today?
SeaStar Medical Secures $23.9M Funding, Hits 50% Enrollment in AKI Trial: SeaStar Medical added 13 pediatric hospital customers, raising its QUELIMMUNE base to 16, secured $23.9 million in capital, and cut $3.1 million in liabilities. It enrolled 181 of 339 patients (over 50%) in its NEUTRALIZE-AKI trial and projects roughly $2 million in net product revenue for 2026.
Does Rallies summarize ICU news?
Yes. Rallies summarizes ICU news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ICU research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ICU. It does not provide personalized investment advice.
ICU

ICU